What is the role of sorafenib (Nexavar) in the treatment of renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

Sorafenib (Nexavar), a small-molecule Raf kinase and VEGF multireceptor kinase inhibitor, is approved by the FDA for the treatment of patients with advanced renal cell carcinoma (RCC). This indication was based on the demonstration of improved progression-free survival in a large, multinational, randomized, double-blind, placebo-controlled phase 3 study and a supportive phase 2 study. [54, 55]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!